Lincoln Pharma Q1 FY26 Net Profit up 16.93% Y-o-Y to ₹27.70 Crore; Targets ₹1,000 Crore Revenue in 3 Years
The announcement includes strong quarterly financial results, re-appointment of key management personnel, and clear future growth strategies and revenue targets. These elements are highly impactful for investor confidence and the company's long-term trajectory.
The company reported significant year-on-year growth in net profit, total income, and EBITDA. The management has set ambitious future revenue targets and growth rates, supported by strategic initiatives like global expansion, new product lines, and FII stake increase, indicating a positive outlook.
* Lincoln Pharmaceuticals Limited reported a standalone net profit of ₹27.70 crore for the quarter ended June 30, 2025 (Q1 FY26), marking a 16.93% year-on-year growth compared to ₹23.69 crore in Q1 FY25. * Total income for Q1 FY26 stood at ₹169.34 crore, a 7.39% increase from ₹157.69 crore in the corresponding quarter of the previous fiscal year. * Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) for Q1 FY26 grew by 17.92% year-on-year to ₹39.08 crore, up from ₹33.14 crore in Q1 FY25. Earnings Per Share (EPS) was ₹13.82. * The Board of Directors re-appointed Mr. Mahendra G. Patel as Managing Director and Mr. Hashmukh I. Patel, Mr. Ashish R. Patel, and Mr. Munjal M. Patel as Whole Time Directors for a period of five years, subject to shareholder approval. Their new terms commence from October 01, 2025, and November 14, 2025, respectively. * M/s Ankit Sethi & Associates was appointed as the Secretarial Auditor for five consecutive years, from April 01, 2025, to March 31, 2030, also subject to shareholder approval. * Mr. Mahendra Patel, Managing Director, stated the company aims to achieve a revenue of ₹1,000 crore within the next three years, driven by business expansion into high-value product lines and new markets. The company targets a 15-18% annual growth rate, focusing on cardiac, diabetic, dermatology, and ENT segments. * Foreign Institutional Investors (FIIs) have increased their stake in the company from 3.95% in June 2024 to 5.13% as of June 2025. * The company has started a Bulk Drug Manufacturing Plant and received product approvals for 10 products, with plans to invest ₹4 crore from internal accruals. * Lincoln Pharmaceuticals plans to expand its global footprint to 90 countries over the next 2-3 years, building on its presence in 60+ countries and recent entries into the Canadian market, TGA-Australia, and EU GMP approvals.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.